AACR 2019: Gilteritinib improved survival for patients with acute myeloid leukaemia
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory…
Browsing: FLT3-mutated AML
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- COVID-19 and Telehealth: Practical guide for cancer clinicians
- FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma
- Mathematical method developed to predict cancer and drug-specific immunotherapy efficacy
- Ultrasound technique treats prostate cancer with minimal side effects
- Landmark research toward increasing survival rates for aggressive childhood cancer
- Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
- Samara Polytech scientists proved the anti-cancer properties of a number of plant extracts
- Combination therapy with radiation shows promise in treating glioblastoma
